NewAmsterdam Pharma Co N.V. Earnings Per Share Disclosure
Note 13. Net Loss per Ordinary Share
Basic and diluted net loss per ordinary share was calculated as follows:
|
|
Year ended December 31, |
|
|||||||||
(In thousands of USD, except share and per share amounts) |
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Net loss |
|
|
(203,819 |
) |
|
|
(241,598 |
) |
|
|
(176,937 |
) |
Weighted average ordinary shares outstanding, basic and diluted |
|
|
118,424,231 |
|
|
|
94,358,067 |
|
|
|
82,161,956 |
|
Net loss per ordinary share, basic and diluted |
|
|
(1.72 |
) |
|
|
(2.56 |
) |
|
|
(2.15 |
) |
The following potentially dilutive securities have been excluded from the computation of diluted weighted-average ordinary shares outstanding as they would be anti-dilutive:
|
|
Year ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Stock options |
|
|
20,625,368 |
|
|
|
19,029,056 |
|
|
|
15,783,509 |
|
Restricted share units |
|
|
728,283 |
|
|
|
143,002 |
|
|
|
— |
|
Outstanding warrants |
|
|
2,490,104 |
|
|
|
2,632,581 |
|
|
|
4,017,221 |
|
Total |
|
|
23,843,755 |
|
|
|
21,804,639 |
|
|
|
19,800,730 |
|
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.